8-K: Establishment Labs Secures Amended Credit Agreement, Extends Loan Deadlines and Modifies Milestones

Establishment Labs has amended its credit agreement, extending loan deadlines and modifying financial milestones for accessing additional funding.

Summary

• Establishment Labs has entered into a second amendment to its credit agreement with Oaktree Fund Administration, LLC.
• The amendment extends the deadline for Tranche C term loans from March 31, 2024, to December 31, 2024.
• The deadline for Tranche D term loans has been extended from December 31, 2024, to June 30, 2025.
• The interest rate for both Tranche C and Tranche D term loans has increased from 9.0% to 10.0% per annum.
• Prepayment premiums have been modified to include a make-whole plus 4% for prepayments within one year of the advance.
• The milestone for Tranche C loan availability is now solely based on FDA approval of Motiva Implants for augmentation use in the U.S., removing the alternative sales target.
• The milestone for Tranche D loan availability is now based on achieving trailing twelve-month gross sales of $195 million, reduced from $225 million.
• Funding of Tranche C loans is now a prerequisite for funding Tranche D loans.
• The terms of Tranche A and Tranche B loans remain unchanged.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company has secured extended deadlines and a reduced sales target, the increased interest rates and reliance on FDA approval introduce some risks. The amendment is likely a necessary step for the company's financial planning.

Positives

• The extension of loan deadlines provides Establishment Labs with more time to meet the conditions for accessing the Tranche C and D loans.
• The reduction in the sales milestone for Tranche D loans from $225 million to $195 million makes it easier for the company to access this funding.

Negatives

• The increase in interest rates from 9.0% to 10.0% per annum on Tranche C and D loans will increase the company's borrowing costs.
• The new prepayment premium structure could make it more expensive to refinance the loans in the short term.

Risks

• The company's ability to access Tranche C funding is now entirely dependent on FDA approval of Motiva Implants, which introduces regulatory risk.
• Failure to achieve the $195 million sales milestone for Tranche D loans by June 30, 2025, could impact the company's access to further funding.
• The increased interest rates will increase the company's debt servicing costs.

Future Outlook

The company's ability to access further funding is contingent on FDA approval of Motiva Implants and achieving the $195 million sales milestone for Tranche D loans.

Management Comments

• The document does not contain any direct quotes from management, but the signing of the amendment by the CEO and CFO indicates their approval and agreement with the terms.

Industry Context

This amendment reflects the ongoing financial needs of Establishment Labs as it seeks to expand its market presence and obtain regulatory approvals for its products. The changes in milestones and deadlines are likely influenced by the company's progress in achieving sales targets and navigating the regulatory approval process.

Comparison to Industry Standards

• The interest rate increase to 10% is relatively high, suggesting that Establishment Labs may be considered a higher-risk borrower compared to more established medical device companies.
• The reliance on FDA approval for a key funding milestone is common in the medical device industry, but the removal of the sales target alternative increases the risk associated with regulatory delays.
• The reduction in the sales milestone for Tranche D loans suggests that the company may have faced challenges in meeting the original target of $225 million, which is not uncommon for companies in the growth phase.

Stakeholder Impact

• Shareholders may view the extended loan deadlines and reduced sales target positively, but the increased interest rates could raise concerns about profitability.
• Lenders will benefit from the increased interest rates and the make-whole premium on prepayments.
• Employees may be indirectly affected by the company's financial stability and ability to fund operations.

Next Steps

• Establishment Labs needs to secure FDA approval for Motiva Implants for augmentation use in the U.S.
• The company needs to achieve trailing twelve-month gross sales of $195 million to access Tranche D funding.
• The company needs to ensure all French and Italian subsidiaries meet the requirements of Section 8.11 of the Credit Agreement within 30 days.

Key Dates

Keywords

credit agreement, loan amendment, term loans, FDA approval, Motiva Implants, interest rate, prepayment premium, financial milestones, Oaktree, funding